FDA Signs Off on Adaptimmune’s Tecelra
Patients with a certain type of synovial sarcoma have a new treatment option for the first time in more than a decade as the…
Carbon
Ferring Receives Approval from U.S. FDA for Adstiladrin
Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer.
Forecasting Medical Costs Enables Timely Intervention
Proactive care management combined with predictive analytics has significant potential to help plans identify members who are likely to become high-cost claimants, allowing for…
Growth of Value-Based Purchasing For Cell & Gene Therapies
Rx Data Reporting Stops Short of Price Transparency PBMs find a way around CMS requirement meant to prevent hidden rebates
Inflation Impacts Healthcare Costs and Self-Insured Benefit Plans
The impact of inflation on the broader economy will likely lead to rising healthcare claim costs in an already inflated high price market. Carbon…
Medicaid Best Price 101
The lowest price available from the manufacturer during the rebate period to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity…
Mesoblast Plans New GvHD Trial After Another FDA Rejection
Mesoblast plans to conduct a new trial for evaluating the efficacy of remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (GvHD),…
Novacore Acquires Three Companies to Establish Medical Stop Loss and Managed Care Platform
NSM acquires three companies to bolster its portfolio of leading specialty insurance productsCONSHOHOCKEN, PA, March 20, 2023 – NSM Insurance Group, the nation’s leading specialty insurance…
Orchard Therapeutics Outlines U.S. Launch Plans For Lenmeldy
Orchard Therapeutics announced the U.S. Food and Drug Administration has approved Lenmeldy™, formerly known as OTL-200, for the treatment of children with pre-symptomatic late…
Otarmeni™️ (lunsotogene parvec-cwha) Approved by FDA
Otarmeni™️ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the…
